3:17 PM ET
8-K
Clinical Trial Data
Braveheart Bio Clinical Trial Data
Braveheart Bio and Hengrui Pharma presented 52-week open-label extension data from a Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM). The results showed meaningful improvements in exercise capacity (pVO2) and patient-reported outcomes, with 79% of patients achieving a Valsalva LVOT gradient below 30 mmHg at Week 52.
- Counterparty
- Hengrui Pharma
- Term
- 52 weeks